AMPH vs. PTGX, FPRX, SNDX, DYN, PAHC, ELAN, ASND, LEGN, CERE, and ITCI
Should you be buying Amphastar Pharmaceuticals stock or one of its competitors? The main competitors of Amphastar Pharmaceuticals include Protagonist Therapeutics (PTGX), Five Prime Therapeutics (FPRX), Syndax Pharmaceuticals (SNDX), Dyne Therapeutics (DYN), Phibro Animal Health (PAHC), Elanco Animal Health (ELAN), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Cerevel Therapeutics (CERE), and Intra-Cellular Therapies (ITCI). These companies are all part of the "medical" sector.
Protagonist Therapeutics (NASDAQ:PTGX) and Amphastar Pharmaceuticals (NASDAQ:AMPH) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, dividends, media sentiment, analyst recommendations, earnings, institutional ownership, valuation, profitability and risk.
Amphastar Pharmaceuticals has higher revenue and earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Amphastar Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Amphastar Pharmaceuticals has a net margin of 22.88% compared to Amphastar Pharmaceuticals' net margin of 0.00%. Amphastar Pharmaceuticals' return on equity of 43.42% beat Protagonist Therapeutics' return on equity.
Protagonist Therapeutics has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500. Comparatively, Amphastar Pharmaceuticals has a beta of 0.85, meaning that its stock price is 15% less volatile than the S&P 500.
98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 65.1% of Amphastar Pharmaceuticals shares are held by institutional investors. 5.4% of Protagonist Therapeutics shares are held by insiders. Comparatively, 27.1% of Amphastar Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Protagonist Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 34.99%. Amphastar Pharmaceuticals has a consensus price target of $66.00, indicating a potential upside of 55.92%. Given Protagonist Therapeutics' higher probable upside, analysts clearly believe Amphastar Pharmaceuticals is more favorable than Protagonist Therapeutics.
Amphastar Pharmaceuticals received 125 more outperform votes than Protagonist Therapeutics when rated by MarketBeat users. Likewise, 66.67% of users gave Amphastar Pharmaceuticals an outperform vote while only 59.73% of users gave Protagonist Therapeutics an outperform vote.
In the previous week, Amphastar Pharmaceuticals had 7 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 11 mentions for Amphastar Pharmaceuticals and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.05 beat Amphastar Pharmaceuticals' score of 0.71 indicating that Amphastar Pharmaceuticals is being referred to more favorably in the news media.
Summary
Amphastar Pharmaceuticals beats Protagonist Therapeutics on 11 of the 18 factors compared between the two stocks.
Get Amphastar Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for AMPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AMPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Amphastar Pharmaceuticals Competitors List
Related Companies and Tools
